Biological effects of brachytherapy using a 32P-patch on the skin of Sencar mice

Salgueiro, M.; Collia, N.; Durán, Hebe; Palmieri, Mónica A.; Medina, Vanina Araceli; Ughetti, R.; Nicolini, J.O.; Zubillaga, Marcela

doi:10.1016/j.apradiso.2009.05.006

Cited by 6 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the indications for CO 2 laser has been expanded to include keloid excision and has shown promising results in increasing the secretion of basic fibroblast growth factor and decreasing the release of transforming growth factor β1 (TGF‐β1), thereby suppressing the formation of granulation (proliferation) tissue . Studies have also shown good results when adding 32 P chromic phosphate or silicon 32 P‐patch to the local treatment for solid tumors or keloids . The topical paste 32 P, causes local irritation, similar to radiation dermatitis, and suppresses fibroblast proliferation.…”

Section: Discussionmentioning

confidence: 99%

A combination of nonoperative treatment modalities used for treatment of keloids

et al. 2013

View full text Add to dashboard Cite

Keloid is one abnormal wound healing that occurs commonly in predisposed individuals. Many treatment modalities have been tried, either alone or in variety, including surgical removal, laser therapy, radiation therapy, silicone cream or gel application, cryosurgery, and intralesional injection of various agents. These treatment options have been practiced with largely transient and limited success. In the present study, the present authors prospectively assessed the efficacy of combination methods of the treatment of recalcitrant keloid. One hundred fifty-one sites of keloids in 122 patients were chosen, age of patients varied between 15 and 60 years, size of scar more than 2 cm(2) with pain, itch, or other discomfort, and duration of more than 2 years. Keloids were treated with combination methods of lasers and (32) P radiation on originating scars. One hundred eleven of 151 evaluated sites scored "excellence" and 40 belonged to "effectiveness". These patients demonstrated local control and have remained free of local recurrence for more than 2 years. In addition, there were only 21 and 32 sites with pigmentation and depigmentation, respectively. Over the past 5 years, we established a treatment protocol combining laser with (32) P-patch contact brachyradiotherapy, which represents a safe and effective option in the treatment of keloids.

show abstract

Section: Discussionmentioning

confidence: 99%

A combination of nonoperative treatment modalities used for treatment of keloids

et al. 2013

View full text Add to dashboard Cite

show abstract

“…32 P is a pure β-particle-emitting radionuclide that has a half-life of 14.3 d. The biologic effects of ionizing radiation, 24–26 benign proliferative diseases, 27 and malignant tumors can be treated using 32 P brachytherapy, a form of radiation therapy. 25 , 26 In this technique, the radiation source is placed close to the area to be treated, 24–27 similar to other surface-mold isotope brachytherapies. 28 The range of electrons emitted by 32 P is limited in that the maximum range in the tissue is 7.5 mm.…”

Section: Discussionmentioning

confidence: 99%

“… 28 The range of electrons emitted by 32 P is limited in that the maximum range in the tissue is 7.5 mm. The therapeutic range of 32 P brachytherapy in tissue is about 2 mm, and the accumulated dose falls to subcritical levels within 10 mm of the radioactive source, thus making this approach safe for treatment of lesions in humans 26–27 and ensuring that surrounding healthy tissue receives only minimal radiation doses. 32 P brachytherapy may be superior to conventional external beam radiation for treating patients who have small, primary, and/or superficial lesions in terms of providing excellent functional and cosmetic results.…”

Section: Discussionmentioning

confidence: 99%

Novel Application of³²P Brachytherapy: Treatment of Angiolymphoid Hyperplasia with Eosinophilia in the Right Auricle with 8-Year Follow-Up

Zhang

Wen

et al. 2018

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Background: Angiolymphoid hyperplasia with eosinophilia (ALHE) is a distinctive benign vascular disease that can be challenging to treat due to inconsistent results for various treatment modalities such as surgical excision, corticosteroids, radiotherapy, laser therapy, and other therapies, so novel approaches are needed to improve treatment outcomes.Materials and Methods: ALHE on the right auricle of a 54-year-old Chinese woman underwent brachytherapy using 32P simple drug membranes for five times. The 32P brachytherapy involving simple drug membranes of brachytherapy began by diluting a 32P solution with 0.9% NaCl solution to produce a radioactivity of 69.2–74.7 MBq/mL(1.87–2.02 mCi/mL). The drug membranes were removed between 48 and 72h after application. There were intervals ranging from 65 to 72d between the membrane application periods, and the last treatment was in June 2010.Results: After the 32P brachytherapy, follow-up results over the course of 8 years were promising. The regional symptoms disappeared, the right preauricular swelling decreased, the subcutaneous nodules decreased in size, the exudate disappeared, and the skin appearance improved.Conclusions: This case indicated that 32P brachytherapy may represent a novel ALHE treatment method that produces a favorable long-term outcome.

show abstract

“…The planning systems used in brachytherapy (BT) techniques tend to result in inaccuracies because of the specific characteristics of this method [ 1 ]. To estimate the response of biological tissues to the deposited energy, the absorbed dose must be accurately estimated [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Standardization and Validation of Brachytherapy Seeds’ Modelling Using GATE and GGEMS Monte Carlo Toolkits

Chatzipapas

Plachouris

Papadimitroulas³

et al. 2021

Cancers

View full text Add to dashboard Cite

This study aims to validate GATE and GGEMS simulation toolkits for brachytherapy applications and to provide accurate models for six commercial brachytherapy seeds, which will be freely available for research purposes. The AAPM TG-43 guidelines were used for the validation of two Low Dose Rate (LDR), three High Dose Rate (HDR), and one Pulsed Dose Rate (PDR) brachytherapy seeds. Each seed was represented as a 3D model and then simulated in GATE to produce one single Phase-Space (PHSP) per seed. To test the validity of the simulations’ outcome, referenced data (provided by the TG-43) was compared with GATE results. Next, validation of the GGEMS toolkit was achieved by comparing its outcome with the GATE MC simulations, incorporating clinical data. The simulation outcomes on the radial dose function (RDF), anisotropy function (AF), and dose rate constant (DRC) for the six commercial seeds were compared with TG-43 values. The statistical uncertainty was limited to 1% for RDF, to 6% (maximum) for AF, and to 2.7% (maximum) for the DRC. GGEMS provided a good agreement with GATE when compared in different situations: a) Homogeneous water sphere, b) heterogeneous CT phantom, and c) a realistic clinical case. In addition, GGEMS has the advantage of very fast simulations. For the clinical case, where TG-186 guidelines were considered, GATE required 1 h for the simulation while GGEMS needed 162 s to reach the same statistical uncertainty. This study produced accurate models and simulations of their emitted spectrum of commonly used commercial brachytherapy seeds which are freely available to the scientific community. Furthermore, GGEMS was validated as an MC GPU based tool for brachytherapy. More research is deemed necessary for the expansion of brachytherapy seed modeling.

show abstract

Biological effects of brachytherapy using a 32P-patch on the skin of Sencar mice

Cited by 6 publications

References 13 publications

A combination of nonoperative treatment modalities used for treatment of keloids

A combination of nonoperative treatment modalities used for treatment of keloids

Novel Application of³²P Brachytherapy: Treatment of Angiolymphoid Hyperplasia with Eosinophilia in the Right Auricle with 8-Year Follow-Up

Standardization and Validation of Brachytherapy Seeds’ Modelling Using GATE and GGEMS Monte Carlo Toolkits

Contact Info

Product

Resources

About

Biological effects of brachytherapy using a 32P-patch on the skin of Sencar mice

Cited by 6 publications

References 13 publications

A combination of nonoperative treatment modalities used for treatment of keloids

A combination of nonoperative treatment modalities used for treatment of keloids

Novel Application of32P Brachytherapy: Treatment of Angiolymphoid Hyperplasia with Eosinophilia in the Right Auricle with 8-Year Follow-Up

Standardization and Validation of Brachytherapy Seeds’ Modelling Using GATE and GGEMS Monte Carlo Toolkits

Contact Info

Product

Resources

About

Novel Application of³²P Brachytherapy: Treatment of Angiolymphoid Hyperplasia with Eosinophilia in the Right Auricle with 8-Year Follow-Up